Acorda Therapeutics (ACOR) Downgraded by ValuEngine

ValuEngine downgraded shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a report released on Friday.

ACOR has been the topic of a number of other reports. Zacks Investment Research raised shares of Acorda Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, October 18th. Cantor Fitzgerald lowered their price objective on shares of Acorda Therapeutics from $18.00 to $16.00 and set a neutral rating on the stock in a research report on Wednesday, November 15th. Jefferies Group boosted their price objective on shares of Acorda Therapeutics from $22.00 to $25.00 and gave the company a hold rating in a research report on Wednesday, November 1st. CIBC started coverage on shares of Acorda Therapeutics in a research report on Thursday, November 9th. They set a market perform rating on the stock. Finally, Oppenheimer started coverage on shares of Acorda Therapeutics in a research report on Thursday, November 9th. They issued a market perform rating and a $27.00 target price for the company. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $21.35.

Shares of Acorda Therapeutics (NASDAQ ACOR) traded up $0.20 on Friday, reaching $24.05. 561,803 shares of the company were exchanged, compared to its average volume of 776,325. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The stock has a market capitalization of $1,114.92, a P/E ratio of -19.88 and a beta of 1.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40.

In other Acorda Therapeutics news, insider David Lawrence sold 31,000 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the sale, the insider now directly owns 5,275 shares of the company’s stock, valued at $145,484.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the sale, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The disclosure for this sale can be found here. Insiders own 7.90% of the company’s stock.

Several institutional investors have recently modified their holdings of ACOR. Teachers Advisors LLC lifted its stake in shares of Acorda Therapeutics by 8.0% in the second quarter. Teachers Advisors LLC now owns 78,886 shares of the biopharmaceutical company’s stock worth $1,554,000 after buying an additional 5,837 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Acorda Therapeutics by 54.2% in the second quarter. TIAA CREF Investment Management LLC now owns 222,351 shares of the biopharmaceutical company’s stock worth $4,380,000 after buying an additional 78,133 shares during the last quarter. Nationwide Fund Advisors lifted its stake in shares of Acorda Therapeutics by 7.4% in the second quarter. Nationwide Fund Advisors now owns 116,316 shares of the biopharmaceutical company’s stock worth $2,291,000 after buying an additional 7,966 shares during the last quarter. Thrivent Financial For Lutherans lifted its stake in shares of Acorda Therapeutics by 8.6% in the second quarter. Thrivent Financial For Lutherans now owns 28,120 shares of the biopharmaceutical company’s stock worth $554,000 after buying an additional 2,220 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Acorda Therapeutics by 65.2% in the second quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after buying an additional 354,304 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2018/02/10/acorda-therapeutics-acor-downgraded-by-valuengine.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply